Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months
Intravascular Ultrasound
Lumen (anatomy)
Bioresorbable scaffold
Everolimus
DOI:
10.4244/eijv9i11a217
Publication Date:
2014-04-23T08:22:34Z
AUTHORS (20)
ABSTRACT
To assess observations with multimodality imaging of the Absorb bioresorbable everolimus-eluting vascular scaffold performed in two consecutive cohorts patients who were serially investigated either at 6 and 24 months or 12 36 months.In ABSORB multicentre single-arm trial, 45 (cohort B1) 56 B2) underwent serial invasive imaging, specifically quantitative coronary angiography (QCA), intravascular ultrasound (IVUS), radiofrequency backscattering (IVUS-VH) optical coherence tomography (OCT). Between one three years, late luminal loss remained unchanged (6 months: 0.19 mm, 1 year: 0.27 2 years: 3 0.29 mm) in-segment angiographic restenosis rate for entire cohort B (n=101) years was 6%. On IVUS, mean lumen, scaffold, plaque vessel area showed enlargement up to years. Mean lumen stable between whereas significant reduction behind struts occurred a trend toward adaptive restrictive remodelling EEM. Hyperechogenicity wall, surrogate bioresorption process, decreased from 23.1% 10.4% dense calcium necrotic core. At count strut cores detected on OCT increased significantly, probably reflecting dismantling scaffold; 98% covered. In (n=101), three-year major adverse cardiac event 10.0% without any thrombosis.The current investigation demonstrated dynamics wall changes after implantation resulting dimensions, low clinical events rate.http://www.clinicaltrials.gov/ct2/show/NCT00856856.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (39)
CITATIONS (195)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....